GLP-1 weight loss care for North Dakota, online.

Telehealth in North Dakota: where things stand

North Dakota regulates physician practice through the North Dakota Board of Medicine under North Dakota Century Code Chapter 43-17. The Board permits licensed physicians to establish a patient relationship and issue prescriptions through telehealth encounters provided the visit meets the standard of care. North Dakota expanded its telemedicine framework under HB 1058 and subsequent legislation, making permanent several pandemic-era flexibilities. The Board's telemedicine guidance allows real-time audiovisual telehealth encounters as a basis for establishing a valid physician-patient relationship.

North Dakota is sparsely populated with specialist access concentrated in Fargo, Bismarck, Grand Forks, and Minot. Residents of the oil patch (Williston, Watford City, Dickinson), the Missouri River breaks, and small agricultural communities across the state often face 100+ mile drives for specialist care. A telehealth evaluation with a North Dakota-licensed physician through Puri removes that barrier. Whether you live in downtown Fargo, Williston, Mandan, or a farm outside Rugby, the clinical review is identical.

Who qualifies for GLP-1 weight loss in North Dakota

Qualification for GLP-1 medication is based on clinical criteria, not geography. A licensed physician will evaluate:

• Your BMI. Most providers follow FDA prescribing guidelines for brand-name products, which typically require a BMI of 30 or greater, or 27 or greater with a weight-related health condition (such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea).
• Your medical history. Certain conditions contraindicate GLP-1 use, including personal or family history of medullary thyroid carcinoma or MEN2, history of pancreatitis, severe gastroparesis, active cancer, and pregnancy or breastfeeding.
• Your current medications. Some medications interact significantly with GLP-1 receptor agonists. A full medication review is part of every intake.
• Your goals and expectations. A provider wants to understand what you are hoping to achieve and whether GLP-1 therapy fits the rest of your life.

If you meet the clinical criteria and have no contraindications, a Puri-affiliated physician licensed in North Dakota may determine that compounded semaglutide or tirzepatide is appropriate. If not, they will explain why and you will not be charged for medication you did not receive.

What to expect from GLP-1 therapy

GLP-1 receptor agonists work by mimicking a hormone the body naturally produces to regulate appetite, slow gastric emptying, and improve insulin sensitivity. The result for most patients is reduced hunger, smaller portion sizes, and gradual weight loss.

Clinical trial data on the brand-name FDA-approved versions (Wegovy, Zepbound) show average weight loss of 12-18% of body weight over 12 months when combined with lifestyle changes. Compounded semaglutide and tirzepatide have not been evaluated for equivalence to brand products, so individual results may vary.

Most patients experience a slow, steady reduction in appetite and weight over the first three months. Side effects, when they occur, are usually mild gastrointestinal symptoms (nausea, constipation, decreased appetite) that improve as the body adjusts. Your provider will start you at a low dose and increase gradually to minimize side effects.

Compounded vs brand-name: what's the difference?

Brand-name semaglutide (Wegovy, Ozempic) and brand-name tirzepatide (Zepbound, Mounjaro) are FDA-approved finished drug products manufactured by Novo Nordisk and Eli Lilly. They have undergone clinical trials, FDA review, and ongoing post-market safety monitoring. They are sold at standard pharmacies and may be partially covered by insurance.

Compounded semaglutide and compounded tirzepatide are custom-prepared by state-licensed compounding pharmacies under a valid prescription. Compounded medications are NOT FDA-approved, have not been evaluated by the FDA for safety or effectiveness, and have not been reviewed for equivalence to brand-name products. The FDA permits compounding of these medications under specific conditions, but a compounded medication is not the same as a brand-name medication and should not be assumed to be identical.

Who should not take GLP-1 medication

GLP-1 medication is not appropriate for everyone. A licensed physician will decline to prescribe if any of the following apply:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
• Personal history of pancreatitis.
• Pregnancy, breastfeeding, or actively trying to conceive.
• Active or recent cancer.
• Severe gastroparesis or other severe gastrointestinal motility disorder.
• Active eating disorder.
• Severe kidney or liver disease.
• BMI that does not meet clinical criteria for weight management medication.
• Residence outside North Dakota (we only prescribe in states where our providers are licensed).

How to get started in North Dakota

The process is straightforward:

1. 1Complete the 5-minute online intake at our assessment page.
2. 2Provide your North Dakota address and verify your residency.
3. 3Wait for physician review (typically within 24 hours).
4. 4If approved, receive your medication at your North Dakota address.
5. 5Use provider messaging for ongoing questions and dose adjustments.

Ready to begin? Start your assessment. A licensed physician eligible to practice in North Dakota will review your information and be in touch.